FibroGen Inc
F:1FG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
FibroGen Inc
F:1FG
|
US |
|
I
|
Iberdrola SA
SWB:IBE1
|
ES |
|
C
|
Carlisle Companies Inc
DUS:CLE
|
US |
FibroGen Inc
FibroGen is a biotechnology company that develops medicines for serious diseases, especially blood disorders, cancer, and fibrosis. Its best-known drug is a treatment for anemia linked to chronic kidney disease, and it has also worked on experimental drugs aimed at blocking tissue scarring and fighting certain tumors. The company’s role is to take drug candidates through research, testing, and, when successful, into commercial use. FibroGen makes money in a few ways: by selling approved medicines where it has commercial rights, by licensing drug rights to partners, and by receiving payments tied to research and development collaborations. Its customers are mainly patients, doctors, hospitals, and pharmaceutical partners, depending on whether a product is sold directly or through a license agreement. In practice, it sits in the middle of the drug value chain, turning lab discoveries into treatments that can be marketed by FibroGen or shared with larger drugmakers. What makes FibroGen different is its focus on specialized biology rather than broad, mass-market drugs. It builds its business around a small number of highly targeted medicines, which means success depends on strong clinical data, regulatory approval, and commercial partnerships. That gives the company a classic biotech profile: high scientific risk, but the chance to create valuable drugs if its research succeeds.
FibroGen is a biotechnology company that develops medicines for serious diseases, especially blood disorders, cancer, and fibrosis. Its best-known drug is a treatment for anemia linked to chronic kidney disease, and it has also worked on experimental drugs aimed at blocking tissue scarring and fighting certain tumors. The company’s role is to take drug candidates through research, testing, and, when successful, into commercial use.
FibroGen makes money in a few ways: by selling approved medicines where it has commercial rights, by licensing drug rights to partners, and by receiving payments tied to research and development collaborations. Its customers are mainly patients, doctors, hospitals, and pharmaceutical partners, depending on whether a product is sold directly or through a license agreement. In practice, it sits in the middle of the drug value chain, turning lab discoveries into treatments that can be marketed by FibroGen or shared with larger drugmakers.
What makes FibroGen different is its focus on specialized biology rather than broad, mass-market drugs. It builds its business around a small number of highly targeted medicines, which means success depends on strong clinical data, regulatory approval, and commercial partnerships. That gives the company a classic biotech profile: high scientific risk, but the chance to create valuable drugs if its research succeeds.
China Transaction: FibroGen completed the sale of its China operations to AstraZeneca for about $220 million, a move described as transformative that extended its cash runway into 2028.
Pipeline Progress: The company initiated a Phase II trial for lead asset FG-3246 (a CD46-targeting ADC for prostate cancer) and expects top-line results from a key combination trial in Q1 2026.
Roxadustat Update: Following a successful FDA Type C meeting, FibroGen will submit a pivotal Phase III protocol for roxadustat in lower-risk MDS by year-end, targeting a significant unmet need.
Cost Reductions: Operating costs for Q3 dropped dramatically (down 86% YoY), and full-year costs are forecasted to be 70% lower than in 2024.
Financials: Q3 revenue rose to $1.1 million, and the company ended September with $121.1 million in cash and equivalents.
Strategic Flexibility: Management is evaluating whether to partner or self-fund the Phase III roxadustat trial, with clarity expected by Q2 2026.
Royalty Liabilities: A $63 million liability relates to royalties payable to NovaQuest from roxadustat sales in partnered regions, not from ADC milestones.
